Press releases - Ultragenyx
2024年10月3日 · Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease. Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at …
Newsroom—Ultragenyx
2024年9月10日 · View the newsroom for Ultragenyx, which includes the latest press releases, presentations, and blog posts.
Ultragenyx: Ready For More Growth After Q3 Earnings Beat
1 天前 · As a result, Ultragenyx maintained their 2024 revenue guidance of $530M-$550M, which would be 225-27% growth year-over-year. Despite their strong top-line marks, Ultragenyx still reported a net ...
Ultragenyx Presents Positive Update on GTX-102 Angelman ...
4 天之前 · NOVATO, Calif., Nov. 09, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced Phase 1/2 data in support of the Phase 3 Aspire study for GTX-102, its ...
Press releases - Ultragenyx Pharmaceutical Inc.
2024年8月29日 · Access news releases, presentations, and blog posts to follow the latest developments at Ultragenyx.
Ultragenyx Receives Breakthrough Therapy Designation for ...
NOVATO, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for setrusumab (UX143 ...
Ultragenyx Receives FDA Agreement to Expand Ongoing Global ...
NOVATO, Calif., May 17, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the U.S. Food and Drug Administration (FDA) has reviewed and agreed to a protocol amendment to the Phase 1/2 study of GTX-102 in pediatric patients with Angelman syndrome that enables the company to harmonize dose ranges in the …